Sanofi is investing €1bn in a new insulin production site in Beijing, marking its largest investment in China. This facility will be the fourth in the country, aiming to supply the local market amidst rising diabetes rates. The investment comes amid EU-China tensions over trade practices. Teljes cikk (Euronews.com)